NR4A1 and breast carcinoma: It has become clear that breast cancers are heterogeneous, with distinct subtypes based on molecular profile (Cancer Genome Atlas Network 2012), and clinically, treatments are increasingly directed toward molecular markers such as the hormone receptors.